➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Moodys
Colorcon
Medtronic

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

HEMANGEOL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Hemangeol, and what generic alternatives are available?

Hemangeol is a drug marketed by Pierre Fabre Derma and is included in one NDA. There are two patents protecting this drug.

This drug has forty-seven patent family members in thirty-one countries.

The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

Drug patent expirations by year for HEMANGEOL
Drug Prices for HEMANGEOL

See drug prices for HEMANGEOL

Recent Clinical Trials for HEMANGEOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Missouri-ColumbiaPhase 0
Columbia UniversityN/A

See all HEMANGEOL clinical trials

Pharmacology for HEMANGEOL

US Patents and Regulatory Information for HEMANGEOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKesson
Harvard Business School
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.